Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 2von Hippel-Lindau Disease 1Kidney Neoplasms 1

Interventions

belzutifan 4Everolimus 2vatalanib 1spartalizumab 1palbociclib 1lenvatinib 1cabozantinib 1PT2385 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × von Hippel-Lindau Disease × PT2385 × Clear all
NCT03108066 2024-09-24

MK-3795-003

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Completed
4 enrolled 11 charts
Genitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡